Fig. 7

High Expression of TXN is associated with poor prognosis in patients with myeloma. a–b TXN expression levels in normal plasma cells and myeloma cells from Dickens and Zhan myeloma microarray datasets. c TXN expression in CD138⁺ and CD138⁻ cells from patients with multiple myeloma. d TXN expression in CD138⁺ samples from patients with newly diagnosed, treated, and relapsed myeloma. e TXN expression in CD138⁻ samples from patients with newly diagnosed, treated, and relapsed myeloma. Expression levels are presented as boxplots and were compared using an unpaired Student’s t test. f–g Kaplan-Meyer analysis of overall survival in Mulligan (f) and Arkansas (g) myeloma microarray. Survival analysis was performed using a log-rank test. *p < 0.05, **p < 0.01, ***p < 0.005, ****p < 0.001